LARGE-SCALE PROCESSING OF BIOLOGICAL MATERIALS

生物材料的大规模加工

• 批准号: 3896978
• 负责人: J SHILOACH
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3896978
• 关键词: Escherichia coli; Mammalia; bacterial toxins; biological products; biotechnology; exotoxins; genetic recombination; mass tissue /cell culture; microorganism mass culture; microorganism resource /registry; tissue /cell culture; tissue resource /registry

The Pilot Plant (Biotechnology) Unit combines several different types of activities. It is responsible for the large-scale production of bacteria, mammalian cells and biologically active compounds from various sources. Parallel to this activity, it is conducting process development work associated with these preparations in order to be able to execute them efficiently. In addition, the unit is carrying on research work not necessarily associated with a current project, but work that has long-term implications for the unit's performance. During the last year, the unit carried out 120 different large-scale preparations, including micro-organism growth in volumes from 10 to 300 liters, mammalian cell growth up to 50 liter volumes and processing of various biological materials. Development work was done in the growth optimization of various recombinant E. coli and other micro-organisms, using the fed batch technique and oxygen enriched air system yielding 100 g/l wet weight of biomass. The bacteria were needed for various products, especially bacterial toxins.

中试工厂（生物技术）单元结合了几种不同类型的 活动它负责细菌的大规模生产， 哺乳动物细胞和各种来源的生物活性化合物。 在开展这项活动的同时，它还在开展程序开发工作 与这些准备工作相关，以便能够执行这些准备工作， 有效地此外，该单位正在进行研究工作， 与当前项目相关，但具有长期性的工作 对单位业绩的影响。 在过去的一年里，该单位进行了120个不同的大规模 制剂，包括微生物生长，体积从10到300 升，哺乳动物细胞生长高达50升的体积和处理 各种生物材料。 开发工作是在各种生长优化中进行的， 重组大肠大肠杆菌和其他微生物， 技术和富氧空气系统产生100克/升湿重的 生物质。这些细菌被用于各种产品，特别是 细菌毒素